Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) generates a steady flow of news as a clinical-stage oncology company advancing RNA-targeted therapeutics for cancer. This news page aggregates press releases and third-party coverage related to TransCode’s development programs, corporate actions, and scientific collaborations, giving readers a centralized view of how the company’s RNA oncology strategy is progressing.
Much of the company’s news focuses on its lead candidate, TTX-MC138, an RNA-based therapeutic designed to inhibit microRNA-10b (miR-10b), which TransCode identifies as a key factor in metastatic cancer. Updates include milestones from its Phase 0 and Phase 1a clinical trials in metastatic solid tumors, reports on safety and pharmacodynamic data, and announcements about advancing TTX-MC138 into Phase 2a studies across selected metastatic indications and minimal residual disease settings.
Readers can also follow news about preclinical research using the TTX platform, such as studies in glioblastoma models demonstrating delivery of TTX-MC138 to brain tumors, target engagement, and extended survival in murine models. These items highlight how TransCode’s nanoparticle platform is being evaluated for systemic delivery of RNA therapeutics to challenging tumor sites.
Beyond clinical and preclinical data, TransCode’s news includes corporate and strategic developments, such as the acquisition of Polynoma and the addition of seviprotimut-L, a polyvalent shed antigen vaccine for stage IIB and IIC melanoma, to its pipeline. Filings and releases also cover financing transactions with affiliates of CK Life Sciences, reverse stock split decisions related to Nasdaq listing requirements, and governance updates including board and executive appointments.
For investors, researchers, and clinicians, following RNAZ news offers insight into TransCode’s progress in metastatic disease, its expanding immuno-oncology and RNA pipeline, and the regulatory and capital markets events that shape its development path. Bookmark this page to review new trial readouts, platform data, and transaction announcements as they are released.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TransCode Therapeutics (NASDAQ: RNAZ) has received approval from the Dana Farber Cancer Institute Institutional Review Board (IRB) to advance its First-in-Human (FIH) Phase 0 clinical trial for TTX-MC138, targeting metastatic lesions in advanced solid tumors. The trial will assess delivery and pharmacokinetics of TTX-MC138 in up to 12 cancer patients. TTX-MC138 inhibits microRNA-10b, a key regulator of metastasis. Preclinical studies show promising results: complete elimination of local metastases in triple-negative breast cancer models and significant regression in pancreatic adenocarcinoma. This trial, conducted under an exploratory Investigational New Drug application, aims to generate critical data for future clinical studies, although it is not designed to demonstrate therapeutic effect. CEO Michael Dudley expressed optimism about the potential impact on cancer treatment.
TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of a provisional patent application titled "Nanoparticles Comprising Payloads and Their In Vivo Delivery" (U.S. patent application 63/456,602) aimed at enhancing its TTX therapeutic delivery platform. This technology seeks to overcome challenges in delivering RNA therapeutics to tumors, which have been hindered by systemic inflammation and toxicity. The application expands the platform's capabilities to include gene editing and mRNA vaccines. CEO Michael Dudley emphasized that this innovation positions TransCode as a leader in targeted delivery systems. The new patent application aligns with the company's goal of providing personalized therapy for cancer patients and adds to its existing intellectual property portfolio, which includes several granted patents.